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Background. The coexistence of neoplasm and abdominal aortic aneurysm (AAA) presents a real management challenge. This
paper reviews the literature on the prevalence, diagnosis, and management dilemmas of concurrent visceral malignancy and
abdominal aortic aneurysm. Method. The MEDLINE and HIGHWIRE databases (1966-present) were searched. Papers detailing
relevant data were assessed for quality and validity. All case series, review articles, and references of such articles were searched for
additional relevant papers. Results. Current challenges in decision making,the eﬀect of majorbody-cavity surgery onan untreated
aneurysm, the eﬀects of major vascular surgery on the treatment of malignancy, the use of EVAR (endovascular aortic aneurysm
repair) as a fairly low-risk procedure and its role in the managementof malignancy, and the eﬀect of other challenging issues such
as the use of adjuvant therapy, and patients informed decision-making were reviewed and discussed. Conclusion.I ns y n c h r o n o u s
malignancy and abdominal aortic aneurysm, the most life-threatening lesion should be addressed ﬁrst. Endovascular aneurysm
repair where possible, followed by malignancyresection, is becoming the preferred initial treatment choice in most centres.
1.Background
Malignancy and aortic aneurysms are common diseases,
particularly among aging population. Nearly three quarters
of malignant cases are diagnosed in people aged 60 years
and over [1]. Abdominal aortic aneurysms occur in about
7-8% of male population over the age of 65 years and is rare
under the age of 55 years [2]. The coexistence of malignant
disease and aortic aneurysm presents a real management
challenge, especially in establishing the therapeutic priorities
and the ideal treatment approach. This study aims at
reviewing the diagnosis modalities and treatment options
and the changes that have taken place with the advances
in the management of both cancer and aortic aneurysms,
particularly with the development of minimally invasive
procedures.
2.Design and Methods
The MEDLINE and HIGHWIRE databases were searched
using the terms (“neoplasms”[MeSH Terms] or “neo-
plasms”[All Fields] or “cancer”[All Fields]) and (“aortic
aneurysm”[MeSH Terms] or “aortic”[All Fields]) and (“an-
eurysm”[All Fields] or “aortic aneurysm”[All Fields]). All
abstracts from the English language articles and foreign
language articles were examined by a single reviewer. Papers
detailingrelevantdatawereassessed forqualityandrelevance
independently by two separate reviewers. All case series,
review articles, and references of such articles were searched
foradditionalrelevantpapers.Papersthatoutlinedtheirrele-
vantexperienceandoutcomeoftheirapproachsuﬃcientlyto
allow comparison were included; articles that failed to detail
the eﬀect of treatment approach on outcome were excluded.
A total of139 articles were identiﬁed. Ofthese 139papers, 75
were case series, 57 were case reports, and 5 were discussion
papers on various aspects of aortic aneurysm and cancer and
all were included in this paper.
3.Incidence
Although the true incidence of concomitant malignancy
and aortic aneurysm is diﬃcult to establish, most centers2 Cardiology Research and Practice
report a low incidence of intra-abdominal malignancy in
patientswithabdominalaortic aneurysm. Malignancieswere
f o u n di n4 %o fA A Ac a s e si no n eo ft h ee a r l i e rr e v i e w s
covering a period of 22 years (Table 1). Some authors report
a much higher incidence rate, with up to 14% of AAA cases
associated with malignancy in one series published in Japan
(Table 1). Based on the natural history of AAA simulated to
matchtheage-speciﬁcprevalencerateformalesubjects,AAA
was estimated to coincidentally occur in 8.3% of patients
with intra-abdominal malignancy. This includes colorectal
cancers detected using virtual colonoscopy [3].
4.Aetiology
Aortic aneurysms are due to degenerative changes in the
aortic wall. Some reports have found an association between
the presence of cancer and mycotic aortic aneurysm. For
instance, Mycobacterium bovis was found in the wall of a
ruptured abdominal aortic and femoral artery aneurysm fol-
lowing intravesical bacillus Calmette-Gu´ erin (BCG) therapy
forbladdercancer[14,15].Listeria monocytogenesinfection
was also found in the wall of a resected thoracic aneurysm
two months before advanced rectal cancer was diagnosed.
The authors believed that the rectal cancer predisposed the
patient to the developmentof an arterial infection associated
with L. monocytogenes [16]. Clostridium septicum mycotic
aortic aneurysm has been reported simultaneously with
colon cancer [17]. The presence of infection inﬂuences the
natural history and management. These ﬁndings do not
establish a causal association but do raise the possibility of
an infective aetiology in a very small number of aneurysms.
5.ClinicalPresentation
Most synchronous abdominal aortic aneurysms and cancers
are found incidentally during the investigation or treatment
stages. Nevertheless, suspicion of the presence of cancer
has been occasionally raised during the workup for aortic
aneurysm and vice verse. Table 2 details some examples of
such cases.
6.Investigations
Computerised tomography (CT) scan is the most common
investigation reported to detect the presence of abdominal
aortic aneurysms concomitantly with visceral malignancies
and vice verse. Occasionally, malignancies are detected inci-
dentally during laparotomy [22] or following an endoscopic
procedure such as bronchoscopy [20], upper gastrointesti-
nal [21], or lower gastrointestinal [23]e n d o s c o p y .V i r t u a l
colonography [3, 24, 25] or whole-body CT scanning [26]
was recommended by some as a more cost-eﬀective strategy
to use in population-based screening programmes but not
widely accepted.
7.Management
There is no consensus on the best management approach for
patientswith simultaneous aortic aneurysm and malignancy.
Several strategies have beenconsidered, namely, to repair the
aneurysm ﬁrst and treat the malignancy later, to resect the
malignancy ﬁrst and repair the aneurysm later, to undertake
both procedures simultaneously, and in some cases to treat
the malignancy and manage the aneurysm conservatively.
Aorticaneurysm repair is aprophylacticprocedureandis
worthwhile where thelifetime risk ofruptureexceedstherisk
from treatment. The prognosis of cancer is therefore central
to the decision making process.
The perceived increase risk of aortic aneurysm rupture
following cancer surgery, the signiﬁcant delay in the treat-
ment of cancer if aneurysm is treated ﬁrst, and the risk of
graft infection are the other important considerations in the
management of concomitant aortic aneurysm and cancer.
Table 3 summarizes the diﬀerent approaches used in the
treatment of diﬀerent patient groups in case series and their
outcome.
8.Discussion
The treatment ofAAAwithcoexisting malignancyrepresents
a challenging issue to the cancer and vascular specialists
in terms of priority, timing, and expected outcome. Most
published papers consist of fairly small case series. Prospec-
tive randomized controlled trials with adequate statistical
power haveunderstandablynot been donein thisarea. In the
absenceofsuchlevelofevidence,onehas tocombinethebest
available evidencewith a sound clinical judgment applied on
each individual case within a multidisciplinary setting.
The management challenge was reﬂected on a survey of
46 general and vascular professors in the USA in 1985 who
gave their responses as to which condition should receive
priorityoftreatment[39].Excisionofthecarcinomaﬁrstwas
favored by about a third of them, repair of the aneurysm ﬁrst
was favored by another third, and the remaining third stated
that they would withhold a decision until laparotomy was
performed. The survey was undertaken in the mid-eighties
and a similar survey in the current era would probably
show diﬀerent opinions, especially with the introduction of
endovascular and laparoscopic approaches and the availabil-
ityof advanced preoperativestaging techniquesand adjuvant
therapy.
There is some evidence that abdominal surgery increases
the risk of aneurysm rupture, especially when the AAA
diameter isover5cm. Baxteret al. [11] from theMayoClinic
reported two AAA ruptures in the immediate postoperative
period following 20 CRC (colorectal cancer) excisions (10%
incidence rate). A similar phenomenon was noted by Lin
et al. from the Michael E. DeBakey Departement of Surgery,
with AAA rupture incidence rate of 6% following CRC
resection [33]. Swanson et al. [40] noted this complication
in ten previously asymptomatic patients with aneurysms
within 36 days of a prior laparotomy, with a mean AAA
diameter of 9.1cm. On the other hand, Durham et al. [41]
prospectively studied 33 patients (29 men, 4 women) with
a known abdominal aortic aneurysm who underwent 45
operations. The estimated risk of rupture was 3% of all
patients undergoing major operation in this study. It was
hypothesized that a reduction in the collagen contents ofCardiology Research and Practice 3
Table 1: Prevalence of aortic aneurysm and concomitantmalignancy.
Source AAA Malignant disease Colorectal cancer Observation period,
yr
Szilagyi et al.,1967 [4]∗ 803 31 (3.9) 9 (1.2) 22
Nora et al., 1989 [5] 3500 NA (the emphasis is
on CRC)
17 (0.5) (those underwent
operations for Ca and AAA) 12
Morris and Colquitt,
1988 [6]
158 (looking at all but
with histologically
proven ca)
20 (12.7) 6 (3.8) 12
Tennant 1990 [7] 247 4 (1.6) 0 5
Oshodi et al., 2000 [8] 676 8 (1.2) 4 (0.6) 20
Tsuji et al., 1999 [9] 162 4 (2.5) 1 (0.6) 10
Matsumoto et al.,
2002 [10] 260 29 (11.2) 16 (6.2) 14
Baxter et al., 2002 [11] 10 872 NA 83 (0.8) 15
Yamamoto et al. [12] 408 (using FOB to
detect CRC) — 6 (1.5%) with cancer and 16
(3.9) with polyps —
Onohara et al. [13] 112 16 (14%) — —
∗This study was performed in the pre CT/Duplex era and therefore unlikely to detect cancer. AAA: abdominal aortic aneurysm. CRC: colorectal cancer. NA:
not applicable. FOB: faecal occult blood.
Table 2: Examples of clinical presentation of aortic aneurysm and/or associated malignancy.
Source Setting No. of
cases Mode of presentation∗
Upchurch and Clair [18] Cancer in aortic
aneurysm case 1c a s e
Ruptured AAA associated with aortocaval ﬁstula
was complicated by C. Septicum sepsis. CRC was
suspected and found on investigations.
Tsui, et al. [19] Cancer in aortic
aneurysm case 1c a s e
Haemoptysis in TAA was initially related to the
aneurysm. Lung cancer was suspected thereafter
and found.
Van Doorn et al. [20] Aortic aneurysm in
cancer case 1c a s e
Sepsis and widened mediastinum developed after
CRC operation. Thoracic aneurysm was
suspected and found.
Mohamed et al. [17] Aortic aneurysm in
cancer case 1c a s e
CT scan in a patient with sepsis and abdominal
pain revealed ruptured aorta with
pseudoaneurysm. Repeated CT scan in another
centre found CRC in pelvis.
Sebastian et al. [21] Cancer in Aortic
aneurysm case 1c a s e Unsettled dysphagia in TAA was investigated
further. Oesophageal cancer was found.
∗AAA: abdominal aortic aneurysm. CRC: colorectal cancer.
aortic wall following trauma may predispose the aortic
aneurysm to rupture, through a mechanism mediated by
collagenase and protease activation [40, 42].
The eﬀect of delayed cancer treatment on the long-
term outcome remains unclear. Ideally, any delay in cancer
management should be avoided. A few months delay before
initiating treatment of oesophageal cancer, for example,
would have an impact on the stage of the cancer, and thereby
on the patients’ prognosis [43]. Nevertheless, disease stage
at the time of diagnosis is probably the most important
inﬂuence on survival, and some delay in treatment may not
strongly be associated with variation in survival [44]. Delays
occurring due to poor organization or the magnitude of
the ﬁrst operation requiring prolonged recovery before the
second operation took place, need to be tackled as modern
practice allows.
Authors from many large centers (the Mayo Clinic,
USA [23], The Cleveland Clinic Foundation, USA [30], the
University of Naples Federico II and University of Turin,
Italy [36, 37], the Michael E. DeBakey Department of
Surgery, USA [8], the Keio University School of Medicine,
Japan [13], the Imperial College London, UK [46], the
Concord Repatriation General Hospital, Australia [31],
and others [16, 45]) agree that the most life-threatening
(or symptomatic) lesion should be addressed ﬁrst. Large
abdominal aortic aneurysms, obstructing colonic cancers, or
bleeding gastric cancers, for example, should be treated ﬁrst
where possible. The treatment modality may be a minimally
invasive procedure (e.g. stenting for obstructing CRC) that
can allow optimization and a better planned therapy [36].
A one-stage operation to repair the aortic aneurysm
and resect the malignancy has the advantage of avoiding a4 Cardiology Research and Practice
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second major abdominal operation, avoiding the potential
risk of ruptured aneurysm following the cancer resection
stage, avoiding the potential delay in cancer treatment
if the aortic aneurysm was addressed ﬁrst, and avoiding
the potential diﬃculty in dealing with adhesions resulting
from an earlier laparotomy [31–33]. Most studies have not
shown any signiﬁcant increase in the risk of graft infection
following a one-staged operation (see Table 3,[ 8, 13, 27,
28, 30, 31, 33–37, 45]). Nevertheless, few reports have
documented a possible correlation between graft infection
and simultaneous open abdominal surgery [27, 46, 47].
The cumulative morbidity and mortality were signiﬁcantly
higher in one-staged operations when compared to two-
staged operations in some reports (Lin et al. [33]), and the
one-staged option as a primary approach was unfavorable
by some authors accordingly (Lin et al. [33]a n dH a f e ze t
al. [31]). Combined operation in cases where both lesions
pose a life-threatening condition (e.g. large aneurysm with
advanced obstructing malignancy) is supported by most
authors, providing a very high attention to details in place
(thoughtful antibiotic coverage and possible irrigation of
operative ﬁeld with antibiotics [32], usage of antibiotic-
bound grafts [23], good-risk patient selection, veriﬁed good
colonic blood supply to avoid necrosis, possible use of
o m e n t a lw r a pa r o u n dt h ev a s c u l a rg r a f t[ 11, 32, 45], possible
spray of ﬁbrin glue around anastomosis [32], using extra-
anatomic bypass instead of a grafted aorta [32], etc.) (Baxter
et al. [11], Lin et al. [33], Robinson et al. [23], Suﬀat et
al. [34], and Shalhoub et al. [36]). Some authors, however,
remain in favor of a combined operation as a primary
management approach to synchronous lesions [8, 13, 31,
32, 34], especially for fairly clean operations such as gastric
[13, 34] or urological cancers [31, 37].
Stagedoperation(repairofaorticaneurysm ﬁrstorresec-
tion of malignancy ﬁrst) has the theoretical advantage of
avoiding major longer operation and avoiding the risk of
cross-contamination and consequent devastating graft infec-
tion. Nevertheless, many reports have shown a signiﬁcant
time delay before the second operation (especially when
malignancy is treated ﬁrst) [8, 11, 33, 35, 38, 48], a high inci-
dence of catastrophic sequelae (ruptured aortic aneurysm in
the case of treating the malignancy ﬁrst) [11, 23, 27, 33], or
a signiﬁcant decrease in the long-term survival, especially
when one pathology was treated eventually [31, 38, 45].
Despite these unfavourable ‘side eﬀects’ of staged opera-
tions, this option (malignancy-ﬁrst or aorta-ﬁrst approach)
remains the preference for some authors [6, 35, 36]. Few
questions such as the impact of aneurysm repair in staged
procedureonthe timing ofadjuvant therapy and theeﬀectof
radiotherapy on the EVAR stent need further well-controlled
studies in the future.
Endovascular aortic repair (EVAR) in the treatment of
concomitant malignancy has attracted much attention more
recently [27, 31, 33, 34, 36, 38]. As EVAR does not involve
a laparotomy, patients recover quickly and in most cases
w o u l db ea b l et ou n d e r g ot h ec a n c e rs u r g e r yw i t h i na
couple of weeks if required. Drury and colleagues [49]
performed a systematic review and meta-analysis of ran-
domized controlled trials on EVAR and showed a persistent
reduction in 30-day mortality (1.6 versus 4.7%) and lower
incidence of major complications (including cardiac, respi-
ratory, and renal) after EVAR procedures when compared
to open procedures [49]. In line with these results, most
authorsdealingwith synchronousAAAandmalignancy have
found a persistent decrease of the interval period between
repairing the aortic aneurysm using EVAR and performing
the malignancy operation in the two-staged approach [27,
33, 36], a persistent reduction in operative morbidity and
mortality [27, 33] that was sustained up to 3-4 years of
followup [27, 33], and a signiﬁcant reduction in length
of hospital stay (unless endoleak has to be ruled out [36,
38]), and in the intraoperative blood loss [27, 33, 36, 50].
Colonicischaemia israre afteran EVARprocedure.However,
recent prior colonic surgery may predispose patients to such
a complication as reported in 2 patients who had right
hemicolectomy (with conﬁrmed patent IMA) followed by a
staged EVAR (18% incidence rate) in one report [33]. Lin
and colleagues recommended using additional preoperative
imaging to conﬁrm the presence of SMA/IMA collateral
ﬂow before embarking on such staged operations [33, 38].
Endovascular aneurysm repair, where possible, followed
by malignancy operation has become the initial preferred
treatment choice in some centers [31, 33, 34, 38]. The risk of
vascular graft infection is also likely to be less with an EVAR
procedure, as there is no risk of direct contamination during
the resection of abdominal malignancy.
Patients with advanced/end-stage malignancy and large
aorticaneurysmrequiresoundethicalconsiderationandbal-
anced clinical judgment [6, 8, 35, 45]. A good understanding
of the expected outcome in each speciﬁc cancer type, as
well as the presence of other comorbidities (age, physiologic
well-being, etc.) is essential for a proper decision making
within a multidisciplinary team approach. Aneurysm repair
would be considered inappropriate if curative resection is
not feasible, even if the EVAR procedure can be carried out
with minimum morbidity. The EVAR II trial is particularly
helpful in this context. Patients who were deemed unﬁt for
open aortic aneurysm repair were randomly allocated to best
medical therapy alone or EVAR and best medical therapy.
The trial was weakened by a signiﬁcant number of patients
that crossed over to undergo aneurysm repair. Nevertheless,
thetrialshowedthatpatientswithsigniﬁcantcomorbiditydo
not show any survival beneﬁts with AAA repair [51]. These
data can be relevant to cancer patients with poor prognosis
who are, on a similar basis, unlikely to beneﬁt from AAA
repair.
The need for adjuvant therapy for cancer treatment is
a n o t h e rf a c t o rt oc o n s i d e rw h e np l a n n i n gf o ras t a g e do r
simultaneous operation [36]. Lauro et al. have raised con-
cerns regarding chemotherapy treatment (associated with
aggressive hydration and corticosteroids) in patients known
to have AAA > 6cm. Such treatment may result in enlarge-
ment of major arteries and may increase the risk of rupture
[42]. There are no documented reports of chemotherapy-
related aneurysm rupture so far. Chemotherapy adminis-
tered to patients before or after EVAR had no consequences
in some reports [36]. Data on the risk of aneurysm rupture
due to chemotherapy is limited and should not be an8 Cardiology Research and Practice
important consideration in management decision. It would
be entirely reasonable to await the response of chemotherapy
and get a better estimate of prognosis before undertaking the
repair of aneurysm.
The extent of nodal dissection has signiﬁcant eﬀect on
the overall cancer prognosis, including the need for adjuvant
therapy. No technical diﬃculties or speciﬁc limitation have
been reported in this respect, including performing a D2
lymphadenectomy in gastric cancer [13] or total mesorectal
excision and full node dissection in rectal cancer [38].
However, a one-staged operation appears to be correlated
with more D2 dissection and less total gastrectomy rate
when compared to staged operations in some series [45].
The eﬀect of paraaortic tissue dissection during open aortic
aneurysm repair on the cancer staging or outcome (in terms
of cancer dissemination or eﬀect on chemoradiotherapy) or
the eﬀect of ﬁnding metastatic malignancy following the
ﬁrst stage of treatment (malignancy-ﬁrst approach) on the
cost-eﬀectiveness of aortic-repair stage [36]r e m a i n st ob e
investigated further.
Treatment priorities and patients’ best interest should be
considered when one of the two lesions is found incidentally
intraoperatively [38]. Treating the most immediate life-
threatening conditionand atwo-staged operation might be a
sensible option in such circumstances. It should be possible
todiagnoseaneurysmsonCTinmostpatientspreoperatively
but malignancy may be occasionally overlooked on the
preoperative CT scan for aneurysms. The increasing use of
EVAR techniques means that most of these lesions will be
detected on preoperative or postoperative surveillance scans
and can be treated in the stages.
The management decision for concomitant malignancy
and aortic aneurysm needs to be made for each individual
case based upon the best estimates of risks of aneurysm rup-
ture, operative risks, prognosis of malignancy, and patient
preference.Therearemultiplevariablesanditwillbediﬃcult
toobtainhigh-levelevidenceforthesepatients. Itistherefore
essential to discuss such cases in a multidisciplinary setting
to achieve a consensus opinion before gaining approval from
the patient on one option or another.
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